An Observational Study in Children With CLN2 Batten Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04462692

Recruitment Status : Not yet recruiting

First Posted : July 8, 2020

Last Update Posted : February 5, 2021

See Contacts and Locations

Sponsor:

Information provided by (Responsible Party):

Regenxbio Inc.

Study Description

Brief Summary:

This is a prospective, longitudinal natural history study to document the progression of ocular manifestations of CLN2 disease among a community-dwelling population of pediatric participants affected by this disease.

Condition or disease
Neuronal Ceroid Lipofuscinosis Type 2 (CLN2)

Detailed Description:

CLN2 is a rare disease with limited available ocular natural history data. While current standard of care slows motor degeneration, it is not known to treat the ocular manifestations of disease. This study is planned to document, through prospective data collection, ocular disease progression in children with a clinical presentation consistent with CLN2 Batten disease undergoing current standard of care for their condition. No investigational product is administered in this observational study.

Study Design

Layout table for study information

Study Type :	Observational
Estimated Enrollment :	50 participants
Observational Model:	Case-Only
Time Perspective:	Prospective
Official Title:	A Prospective, Observational Study to Evaluate Ocular Disease Progression in Children With CLN2 Batten Disease
Estimated Study Start Date :	March 31, 2021
Estimated Primary Completion Date :	October 2023
Estimated Study Completion Date :	October 2023

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: CLN5 disease CLN8 disease CLN1 disease CLN7 disease CLN10 disease CLN3 disease CLN6 disease CLN2 disease CLN4 disease

Genetic and Rare Diseases Information Center resources: Adult Neuronal Ceroid Lipofuscinosis Neuronal Ceroid Lipofuscinosis

U.S. FDA Resources

Groups and Cohorts

Outcome Measures

Primary Outcome Measures :

Change in retinal structure in children with CLN2 Batten disease [ Time Frame: 96 weeks ]
As assessed by SD-OCT measures over time.

Secondary Outcome Measures :

Change in visual function [ Time Frame: 96 weeks ]
As assessed by visual acuity over time.
Change in visual function [ Time Frame: 96 weeks ]
As assessed by pupillary light reflex over time.

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information

Ages Eligible for Study:	Child, Adult, Older Adult
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Children with CLN2 Batten disease undergoing current standard of care for their condition.

Criteria

Inclusion Criteria:

A participant is eligible to be included in the study only if all of the following criteria apply:

His or her legal guardian(s) is(are) willing and able to provide them written, signed informed consent.
Has documented diagnosis of CLN2 disease due to TPP1 deficiency, or has a relative clinically diagnosed with CLN2 with the same mutation as the participant
Is currently receiving biweekly ERT treatment with cerliponase alfa

Exclusion Criteria:

A participant is excluded from the study if any of the following criteria apply:

Has had prior treatment with an adeno-associated virus-based AAV gene therapy
Is currently participating in a clinical trial of investigational product for the treatment of CLN2 disease

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04462692

Contacts

Layout table for location contacts

Contact: REGENXBIO Patient Advocacy	866-860-0117	patientadvocacy@regenxbio.com

Sponsors and Collaborators

Regenxbio Inc.

More Information

Layout table for additonal information

Responsible Party:	Regenxbio Inc.
ClinicalTrials.gov Identifier:	NCT04462692
Other Study ID Numbers:	RGX-381-9101
First Posted:	July 8, 2020 Key Record Dates
Last Update Posted:	February 5, 2021
Last Verified:	February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:	No

Layout table for additional information

Studies a U.S. FDA-regulated Drug Product:	No
Studies a U.S. FDA-regulated Device Product:	No

Keywords provided by Regenxbio Inc.:


CLN2, Batten Disease

Additional relevant MeSH terms:

Layout table for MeSH terms

Neuronal Ceroid-Lipofuscinoses Heredodegenerative Disorders, Nervous System Neurodegenerative Diseases Nervous System Diseases Genetic Diseases, Inborn	Lipidoses Lipid Metabolism, Inborn Errors Metabolism, Inborn Errors Lipid Metabolism Disorders Metabolic Diseases

To Top